- Details
- Thomas Powles joins Charles Ryan discuss toxicity management and the most common toxicities you see in a bladder cancer population with checkpoint inhibitor therapy. Dr. Powles covers three main areas of toxicity management which include going twice as long once you've started immunosuppressants, starting steroids at a grade two toxicity, and the need to educate our patients to put them at the hea...
|
- Details
- Morgan Roupret joins Charles Ryan to speak about the increase in bladder cancer in younger individuals and in particular younger women. Dr. Roupret explains the clinical issues that challenge clinicians when managing younger bladder cancer patients. Biographies: Morgan Roupret, MD, PhD, Professor of Urology, Sorbonne Université, Paris (UPMC), ESOU chairman, Paris, France Charles J. Ryan, MD , the...
|
- Details
- Neal Shore and colleague, Jonathan Rubenstein provide an update on the advances and developments that have been communicated in regards to the truly important challenge of BCG shortage for the use of patients with a high-risk non-muscle invasive bladder cancer. This is an international problem. In a previous program Neal Shore, Ashish Kamat, and Jonathan Rubenstein talked about alternative dosing...
|
- Details
- Jens Bedke, MD discusses the multimodal approach for the treatment of bladder cancer from the surgeon's perspective. While cystectomy offers the greatest benefit to most patients, Dr. Bedke emphasizes the importance of differentiating patients, tumor types and tumor grades to guide patient care. Along with the role of neoadjuvant chemotherapy, Dr. Bedke discusses treatment approaches for the varia...
|
- Details
- Thomas Powles, MD, and Charles Ryan, MD share in a discussion regarding the use of immunotherapy in the peri-operative setting for bladder cancer and the current state of immunotherapy for bladder cancer. Dr. Powles, while excited about the evolving role of immunotherapy, is less enthusiastic on the use of combination immune therapy based on recent findings. Monotherapy with either atezolizumab (A...
|
- Details
- Josh Meeks discusses the bladder cancer data from the ASCO GU 2019 meeting that is compelling from the perspective of urologists in this conversation with Alicia Morgans. Biographies: Josh J. Meeks, MD, PhD, Assistant Professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, Chicago Illinois Alicia Morgans, MD, MPH , Associate Professor of...
|
- Details
- Sia Daneshmand discusses the history of fast-tracked and streamlined post-operative cystectomy care for patients and associated improved outcomes in his conversation with Ashish Kamat. He details the development of the ERAS protocol and the significant milestones that have been realized in this journey to improved patient outcomes after cystectomy. Biographies: Siamak Daneshmand, MD Dr. Sia Danesh...
|
- Details
- Thomas Powles discusses the current state of immunotherapy in the treatment of muscle-invasive bladder cancer (MIBC) specifically in the second-line after cisplatin-based chemotherapy with Chuck Ryan. He discusses the recent learnings that immunotherapy offers a long-term durable response in 10 - 20% of the cisplatin-eligible patient population who are biomarker positive. They discuss ongoing clin...
|
- Details
- Jean Hoffman-Censits joins Alicia Morgans and shares details on the Johns Hopkins women’s bladder cancer program. This program is created in recognition of the pathway that women frequently take in the diagnosis of their bladder cancer. We often see a delay in the diagnostic process of bladder cancer in women compared to men. This delay in diagnosis leads to what is thought to be stage migration....
|
- Details
- Piyush Agarwal reflects on a debate at the EAU 2019 where he debated Seth Lerner, MD who is a preeminent urologist in bladder cancer. Dr. Lerner was favoring open surgery and Dr. Agarwal was favoring robotic surgery for the purpose of the debate as he conveys the positioning of the arguments with Charles Ryan. If you look at the robotic literature in urologic cancers, there is no evidence of any o...
|
